Theragen Etex Co (XKRX:066700) Short-Term Debt & Capital Lease Obligation : ₩47,413 Mil (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Theragen Etex Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Theragen Etex Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₩47,413 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Theragen Etex Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₩2,609 Mil.

Theragen Etex Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Theragen Etex Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theragen Etex Co Short-Term Debt & Capital Lease Obligation Chart

Theragen Etex Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

32,757.70

34,366.69

28,791.06

35,340.25

47,787.41

Theragen Etex Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															35,141.50	41,348.05	49,947.79	47,787.41	47,412.73

Theragen Etex Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Theragen Etex Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Theragen Etex Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Theragen Etex Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Theragen Etex Co Ltd (XKRX:066700) » Definitions » Short-Term Debt & Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

58, Sandan-ro 68-gil, Danwon-gu, Gyeonggi-do, Ansan-si, KOR

Website

http://www.theragenetex.com

Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.

Theragen Etex Co Headlines

No Headlines